CN114933589B - 基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 - Google Patents
基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114933589B CN114933589B CN202210470131.0A CN202210470131A CN114933589B CN 114933589 B CN114933589 B CN 114933589B CN 202210470131 A CN202210470131 A CN 202210470131A CN 114933589 B CN114933589 B CN 114933589B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- fgfr
- added
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 61
- 108091008794 FGF receptors Proteins 0.000 title claims abstract description 36
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 230000015556 catabolic process Effects 0.000 title claims abstract description 14
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 14
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title claims abstract description 11
- 239000003446 ligand Substances 0.000 title claims abstract description 9
- 102000015367 CRBN Human genes 0.000 title claims abstract description 7
- 230000001939 inductive effect Effects 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000017854 proteolysis Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 13
- -1 hexafluorophosphate Chemical compound 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000007821 HATU Substances 0.000 description 10
- 238000004896 high resolution mass spectrometry Methods 0.000 description 10
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 6
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- QCCMGUIQAVRUGI-UHFFFAOYSA-N ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=CC=C(C=C1)N1CCN(CC1)CC(=O)O)=O Chemical compound ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=CC=C(C=C1)N1CCN(CC1)CC(=O)O)=O QCCMGUIQAVRUGI-UHFFFAOYSA-N 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 229940126864 fibroblast growth factor Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100032783 Protein cereblon Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- XCWRDYGFNOMORC-UHFFFAOYSA-N 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-1-[6-(4-piperazin-1-ylanilino)pyrimidin-4-yl]urea Chemical compound COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C=2N=CN=C(NC=3C=CC(=CC=3)N3CCNCC3)C=2)=C1Cl XCWRDYGFNOMORC-UHFFFAOYSA-N 0.000 description 3
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108010026668 snake venom protein C activator Proteins 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- RXFHRKPNLPBDGE-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RXFHRKPNLPBDGE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LCQFHEIDCMPNAN-UHFFFAOYSA-N 2,6-dichloro-3,5-dimethoxyaniline Chemical compound COC1=CC(OC)=C(Cl)C(N)=C1Cl LCQFHEIDCMPNAN-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- WYIGFEKILOYHCT-UHFFFAOYSA-N 4-(2-aminoethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C=2C(NCCN)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O WYIGFEKILOYHCT-UHFFFAOYSA-N 0.000 description 1
- YVIZBYPPHMBVPA-UHFFFAOYSA-N 4-(8-aminooctylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NCCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O YVIZBYPPHMBVPA-UHFFFAOYSA-N 0.000 description 1
- FOHDGJCYBZWKCE-UHFFFAOYSA-N 6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexanoic acid Chemical compound OC(=O)CCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O FOHDGJCYBZWKCE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IJDAOSIFULSGHH-UHFFFAOYSA-N 8-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O IJDAOSIFULSGHH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- MXTVTMKDXQPHNP-UHFFFAOYSA-N C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCCCCCCC(=O)O Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCCCCCCC(=O)O MXTVTMKDXQPHNP-UHFFFAOYSA-N 0.000 description 1
- 108010088874 Cullin 1 Proteins 0.000 description 1
- 102100039195 Cullin-1 Human genes 0.000 description 1
- 102100028907 Cullin-4A Human genes 0.000 description 1
- 101710159242 Cullin-4A Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100502742 Danio rerio fgf8a gene Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101150081124 FGFR gene Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101100275693 Homo sapiens CRBN gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- WEPAAESBMNSHJA-UHFFFAOYSA-N NCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound NCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O WEPAAESBMNSHJA-UHFFFAOYSA-N 0.000 description 1
- KFHRVSOIOPAUND-UHFFFAOYSA-N NCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound NCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O KFHRVSOIOPAUND-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种基于CRBN配体诱导FGFR降解的化合物，包括式(I)所示的化合物或其药学上可接受的盐、水合物：其中，X为 n为3‑11的整数，m为2‑10的整数，h为1‑5的整数。本发明还公开了所述化合物的制备方法和药物组合物，以及所述化合物和药物组合物在在制备预防和/或治疗癌症的药物中的应用。本发明的化合物仅需较少用量即可诱导蛋白降解，这个过程类似于催化反应，并不需要等摩尔量的药物，能减轻对人体的毒副作用。
Description
技术领域
本发明涉及药物化合物合成领域，尤其涉及一种基于CRBN配体诱导FGFR降解的化合物及其制备方法和应用。
背景技术
Cereblon是由人类CRBN基因编码的蛋白，CRBN同源基因是高度保守的，这表明它在生理学中的重要性。Cereblon与损伤DNA结合蛋白1(DDBl)、Cullin-4A(CUL4A)以及Cullin-1调节器(ROCI)组成E3泛素连接酶复合体，该复合体能泛素化一系列蛋白，但具体机制尚不清楚。Cereblon泛素化靶蛋白导致成纤维细胞生长因子8(FGF8)和成纤维细胞生长因10(FGF10)增多，说明泛素化酶复合体对于胚胎肢体生长十分重要。
研究表明，BGJ398是一种有效的选择性FGFR抑制剂，对FGFR1、FGFR2、FGFR3的选择性比FGFR4和VEGFR2高40倍以上。Ⅰ期临床试验中，BGJ398在有FGFR基因畸变的晚期实体瘤患者中显示了很强的抗肿瘤活性、良好的耐受性和安全性，其中最大耐受剂量为125mg·d-1。一项Ⅱ期临床试验评估BGJ398的毒性可以控制，并且对含FGFR2融合的化疗难以治疗的胆管癌具有明显的肿瘤抑制活性。另一项Ⅱ期临床试验评估BGJ398对有FGFR3突变的膀胱尿路上皮癌患者的疗效，受试者每4周给药3周，125mg·d-1，直至出现不可耐受的毒性反应或疾病进展，总缓解率为25.4％，另外38.8％患者疾病稳定。
成纤维细胞生长因子受体(FGFRs)家族是受体酪氨酸激酶(RTK)超家族的一员，包括FGFR1、FGFR2、FGFR3和FGFR4，由4个独立基因编码，具有较高的序列同源性。FGFR能与其天然配体成纤维细胞生长因子(FGF)结合，进行二聚化和自磷酸化，从而激活下游信号转导通路。FGF/FGFR信号通路能调控细胞的增殖、分化和存活，在早期胚胎发育、器官形成、血管生成、组织修复以及代谢调控过程中起重要作用。
研究表明，除了正常生理作用外，FGF和FGFR亦可能作为致癌基因，不仅可驱动肿瘤细胞的增殖，还可介导肿瘤细胞对细胞毒性剂和靶向剂的耐药性。FGFR易通过基因扩增、点突变和染色体易位等形式异常激活。在鳞状非小细胞肺癌、乳腺癌及食道癌中观察到了FGFR1的扩增，在胃癌和乳腺癌中发现了FGFR2的扩增，在膀胱癌、子宫内膜癌和肺鳞状细胞癌中观察到FGFR的激活点突变，在多发性骨髓瘤中观察到易位、FGFR3的扩增和突变。因此，FGFR各亚型的异常可能与肿瘤的发生发展密切相关，FGFR已成为一个极具吸引力的肿瘤治疗靶点，多个FGFR小分子抑制剂正处于临床研究阶段。
研究表明，抑制FGFR往往需要将药物长期维持在较高的浓度，有可能造成严重的副作用，长期使用会导致耐药问题，降低FGFR抑制剂的抗肿瘤效果。并且多靶点FGFR小分子抑制剂由于缺乏选择性，可能存在较多的毒副作用。因此，亟待开发一种抗肿瘤效果优于FGFR抑制剂，并可以降低药物使用剂量，减轻毒副作用的新型FGFR家族内部选择性蛋白降解靶向联合体(PROTACs)。
发明内容
本发明提供了一种基于CRBN配体诱导FGFR降解的化合物及其药物组合物，该化合物或其药物组合物不仅具有优异的FGFR蛋白降解作用和抗癌活性，还能减轻对人体的毒副作用，可用于制备抗肿瘤药物。
本发明的技术方案如下：
一种基于CRBN配体诱导FGFR降解的化合物，包括式(I)所示的化合物或其药学上可接受的盐、水合物：
其中，X为n为3-11的整数，m为2-10的整数，h为1-5的整数。
本发明通过使用连接链将FGFR小分子抑制剂和E3泛素连接酶复合体中Cereblon蛋白配体进行连接，制得一种蛋白降解靶向联合体(PROTACs)双功能小分子，通过对FGFR进行泛素化标记，能够选择性诱导FGFR蛋白降解，具有较好的抗肿瘤活性。
优选的，n为5-11的整数；m为2-8的整数；h为1-4的整数。优选的化合物具有较好的诱导FGFR降解作用和抗肿瘤活性。
最优选的，n为5、7、9或11；m为2、5或8；h为1-4的整数。优选的化合物具有更好的诱导FGFR降解作用和抗肿瘤活性。
本发明所述的化合物还包括式(I)所示的化合物的立体异构体。本发明化合物的所有立体异构体，包括但不限于非对映异构体、对映异构体和阻转异构体以及他们的混合物(如外消旋物)，均包括在本发明的范围内。
本发明所述的化合物还包括式(I)所示的化合物的互变异构体。属于“互变异构体”或“互变异构形式”是指经由低能垒相互转化的不同能量的结构异构体。
本发明所述的化合物还包括式(I)所示的化合物的衍生物的前药，式(I)所示的化合物的衍生物自身可能具有较弱的活性甚至没有活性，但是在给药后，在生理条件下(例如通过代谢、溶剂分解或另外的方式)被转化成相应的生物活性形式。
本发明所述的化合物还包括式(I)所示的化合物的药学上可接受的盐包括与下列酸形成的加成盐：盐酸、氢嗅酸、硫酸、磷酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、茶二磺酸、乙酸、丙酸、乳酸、三氟乙酸、马来酸、柠檬酸、富马酸、草酸、酒石酸或苯甲酸；以及盐酸、氢嗅酸、硫酸、柠檬酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、三氟乙酸、马来酸、苯磺酸或琉珀酸的酸成盐。
本发明还提供了式(I)所示的化合物的制备方法，包括如下步骤：
(1)将式(VII)所示的化合物与式(Ⅱ)所示的化合物溶于有机溶剂，反应得到式(Ⅲ)所示的化合物；
(2)将取代苯胺和固体三光气反应；在加入式(Ⅲ)所示的化合物进行反应，得到式(IV)所示的化合物；
(3)将式(IV)所示的化合物脱除Boc保护，得到式(V)所示的化合物；
(4)将式(Ⅵ)所示的化合物、式(V)所示的化合物、缩合剂溶于有机溶剂进行反应，得到式(I)所示的化合物；
其中，X为n为3-11的整数，m为2-10的整数，h为1-5的整数。
上述步骤的反应式如下所示：
其中，X为n为3-11的整数，m为2-10的整数，h为1-5的整数；
其中：(a)异丙醇、N,N-二异丙基乙胺、室温搅拌；(b)正丁醇、N,N-二异丙基乙胺、甲胺、120℃；(c)2,6-二氯-3,5-二甲氧基苯胺、三光气、四氢呋喃、N,N-二异丙基乙胺、甲苯、冰浴、80℃；(d)二氯甲烷、三氟乙酸；(e)HATU、N,N-二异丙基乙胺、N,N-二甲基甲酰胺。
本发明还提供了一种药物组合物，包括式(I)所示的化合物或其药学上可接受的盐、水合物；还包括药学上可接受的赋形剂。
在所述的药物组合物中，式(I)所示的化合物或其药学上可接受的盐、水合物作为活性成份，与药学上可接受的赋形剂混合制成药物组合物。所述的赋形剂为用于药学领域的稀释剂、辅助剂或载体。
在药物组合物中加入药学上可接受的辅料制成的临床上可接受的剂型。所述剂型为注射剂、片剂或胶囊剂。
本发明还提供了一种药物组合物，包括式(I)所示的化合物或其药学上可接受的盐、水合物，和不同的抗肿瘤药剂。本发明所述的化合物或其药学上可接受的盐、水合物可作为抗肿瘤药剂单独使用，还可以与不同的抗肿瘤药剂联合使用，用于治疗或预防肿瘤。
本发明还提供了式(I)所示的化合物或其药学上可接受的盐、水合物在制备预防和/或治疗癌症的药物中的应用。
本发明还提供了所述的药物组合物在制备预防和/或治疗癌症的药物中的应用。
所述的癌症为多发性骨髓瘤、胃癌、肺癌、乳腺癌、食管癌、结肠癌、髓母细胞瘤、急性粒细胞白血病、慢性白血病、前列腺癌、肝细胞瘤、肾细胞瘤、宫颈癌、皮肤癌、卵巢癌、结肠癌、神经胶质瘤、甲状腺癌或胰腺癌。
与现有技术相比，本发明的有益效果为：
(1)本发明式(I)所示的双功能小分子可以对FGFR进行泛素化标记，仅需较少用量即可诱导蛋白降解，这个过程类似于催化反应，并不需要等摩尔量的药物，能减轻对人体的毒副作用；
(2)本发明体外抗肿瘤活性测试及体外FGFR2、3蛋白降解活性测试表明，式(I)所示的双功能小分子表现出了优异的FGFR2、3蛋白降解作用和抗癌活性，其抗癌效果优于FGFR抑制剂BGJ398，可用于预防或/和治疗多种癌症，在医药领域具有巨大的应用前景。
附图说明
图1为实施例1、4、6和7制得的化合物以及化合物BGJ398对FGFR的降解效果图，其中(a)为BGJ398，(b)为ML-1，(c)为ML-4，(d)为ML-6，(e)为ML-7。
具体实施方式
下文中提供的实施例和制备例进一步阐明和举例说明本发明化合物及其制备方法。应当理解，下述实施例和制备例的范围并不以任何方式限制本发明的范围。本发明的原料可以从商业途径获得或通过本领域已知的方法制备。
化合物的结构通过核磁共振(1H-NMR)和高分辨质谱(HRMS)来确定，NMR测定是用ACF-400BRUK型核磁共振仪，测定溶剂为氘代氯仿(CDC13)或氘代二甲亚砜(DMSO-D6)。柱层析采用200-300目硅胶。
其中，X为n为3-11的整数，m为2-10的整数，h为1-5的整数。
化合物(Ⅴ)的制备方法如下：
(1)将4,6-二氯嘧啶(Ⅶ)(1.50g，11mmol)加入到100mL单口瓶并完全溶解于30mL异丙醇(i-PrOH)中，加入3倍当量的N,N-二异丙基乙胺(DIPEA)(5.3mL，30mmol)于室温下搅拌下滴加10mL i-PrOH溶解的1-Boc-4-(4-氨基苯基)哌嗪(Ⅱ)(2.77g，10mmol)。将反应置于40℃下反应过夜。将反应液过滤，适量乙醇洗固体产物，得到灰白色固体。
(2)将上一步所得灰白色固体(1.92g，5mmol)加入到35mL耐压管中，加入15mL溶剂正丁醇，加入N，N-二异丙基乙胺(2.8mL，15mmol)，加入5mL甲胺的乙醇溶液。密闭于120℃温度下反应过夜。于65℃水浴加热真空下旋干溶剂正丁醇，得到当量的白色固体(Ⅲ)。
(3)将取代苯胺(444mg，2mmol)和固体三光气(296.7mg，1mmol)加入到100mL单口瓶中，加入20mL无水THF溶解，溶液超声溶解至澄清后置-10℃搅拌下缓慢滴加三乙胺(1.1mL，8mmol)。加完后移至室温反应，待反应30min后加热至80℃回流反应1h。旋干溶剂THF，真空下抽干残余少量溶剂，得到淡黄色固体备用。
(4)将化合物(Ⅲ)(768mg，2mmol)加入到步骤(3)的100mL圆底烧瓶中，加入30mL甲苯溶解，加入有机碱DIPEA(1.5mL，8mmol)，于80℃下反应过夜。旋干溶剂甲苯，加入DCM(二氯甲烷)与H2O萃取(DCM 50mL×3/20mL H2O)，合并有机项，无水硫酸钠干燥。过柱分离，使用展开剂极性梯度DCM:MeOH＝100:1-80:1-50:1。使用石油醚/丙酮体系进行重结晶。过夜，析出白色固体(Ⅳ)。
(5)将化合物(Ⅳ)加入25mL圆底烧瓶中，加入5mLDCM完全溶解，于室温搅拌下加入5mL的三氟乙酸，加完后室温条件下反应2h。真空旋干溶剂，加入适量四氢呋喃溶解，在冰浴条件下滴加饱和碳酸氢钠水溶液，加至一定程度有白色固体析出，加到没有固体继续析出时停止滴加，在冰浴条件下继续搅拌0.5h待固体完全析出。将反应经过漏斗抽滤，适量水洗去残留的NaHCO3，将漏斗置于真空干燥除水或者烘箱除水，得到白色固体(Ⅴ)。
(6)将化合物(Ⅵ)、HATU(2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯)、DIPEA、加入溶剂DMF(N,N-二甲基甲酰胺)中，室温搅拌15min，加入化合物(Ⅴ)，室温搅拌30min反应结束，向反应瓶中加入50mL水，用二氯甲烷(20mL×3)萃取，合并有机相，用饱和食盐水(100mL×3)洗涤有机相，旋干有机相，硅胶色谱柱分离纯化得到化合物(I)。
实施例1：
制备：2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)-N-(2-(2-(2,6-二氧哌啶-3-基)-1，3-二氧异吲哚啉-4-基)氨基)乙基)乙酰胺(ML-1)
制备方法：将2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酸酸30mg加入1.5mLDMF中，加入HATU 29mg，N,N-二异丙基乙胺45μL，室温下搅拌15min，加入4-((2-氨基乙基)氨基)-2-(2,6-二氧代哌啶-3-基)异二氢吲哚-1,3-二酮16mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-1。
产物ML-1的核磁共振表征如下：1H NMR(400MHz,DMSO-d6)δ12.02(s,1H),11.07(s,1H),9.42(s,1H),8.33(s,1H),7.58–7.47(m,1H),7.36(d,J＝8.4Hz,3H),7.16(d,J＝8.7Hz,1H),6.97(dd,J＝16.0,7.0Hz,1H),6.84(s,3H),6.67(t,J＝6.0Hz,1H),6.35(s,1H),5.00(dd,J＝12.9,5.4Hz,1H),3.88(s,8H),3.32(d,J＝61.6Hz,6H),3.12–2.72(m,7H),2.52(td,J＝18.5,18.0,9.1Hz,6H).HRMS m/z:calcd for C41H43Cl2N11O8[M+H]+887.3,found 888.34。
实施例2：
制备2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)-N-(8-(2-(2,6-二氧哌啶-3-基)-1,3-二氧异吲哚-4-基)氨基)辛基)乙酰胺(ML-2)
制备方法：将2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酸酸30mg加入1.5mLDMF中，加入HATU 29mg，N，N-二异丙基乙胺45μL，室温下搅拌15min，加入4-((8-氨基辛基)氨基)-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮20.4mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-2。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),9.45(s,1H),8.36(s,1H),7.59(s,1H),7.48(t,1H),7.24–7.14(m,3H),7.07(d,J＝7.1Hz,1H),6.94(d,2H),6.86(d,J＝8.6Hz,1H),6.52(s,1H),6.22(t,J＝5.6Hz,1H),6.10(s,1H),4.91(dd,J＝12.0,5.4Hz,1H),3.91(s,6H),3.34–3.17(m,8H),3.08(s,2H),2.92–2.63(m,7H),1.63(q,J＝7.1Hz,2H),1.58–1.48(m,2H),1.44–1.20(m,12H).HRMS m/z:calcd forC47H55Cl2N11O8[M+H]+971.4,found 972.72。
实施例3：
制备3-(2,6-二氯-3,5-二甲氧基苯基)-1-(6-((4-(4-(12-((2-(2,6-二氧代哌啶-3-基)-1,3)-二氧代异吲哚啉-4-基)氨基)十二烷基)哌嗪-1-基)苯基)氨基)嘧啶-4-基)-1-甲基脲(ML-3)
制备方法：将12-((2-(2,6-二氧哌啶-3-基)-1,3-二氧异吲哚啉-4-基)氨基)十二酸27mg加入1.5mLDMF中，加入HATU 32mg，N,N-二异丙基乙胺51μL，室温下搅拌15min，加入3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基-1-(6-((4-(哌嗪-1-基)苯基)氨基)嘧啶-4-基)尿素30mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-3。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.54(s,1H),9.51(s,1H),8.37(s,1H),7.52–7.39(m,1H),7.24(d,J＝8.1Hz,2H),7.05(dd,J＝15.7,7.1Hz,1H),7.00–6.94(m,3H),6.85(dd,J＝16.2,8.5Hz,1H),6.51(s,1H),6.28–6.18(m,1H),6.11(s,1H),4.91(dd,J＝12.1,5.3Hz,1H),3.91(s,6H),3.80(t,J＝5.3Hz,2H),3.65(t,J＝5.1Hz,2H),3.30(s,3H),3.29–3.09(m,6H),3.02–2.64(m,3H),2.37(t,J＝7.6Hz,2H),1.70–1.57(m,5H),1.43–1.15(m,14H).HRMS m/z:calcd for C49H58Cl2N10O8[M+H]+984.4,found 1007.4。
实施例4：
制备3-(2,6-二氯-3,5-二甲氧基苯基)-1-(6-((4-(4-(8-((2-(2,6-二氧哌啶-3-基)-1,3)-二氧代异吲哚啉-4-基)氨基)辛酰基)哌嗪-1-基)苯基)氨基)嘧啶-4-基)-1-甲基脲(ML-4)
制备方法：将8-((2-(2,6-二氧哌啶-3-基)-1,3-二氧异吲哚啉-4-基)氨基)辛酸23mg加入1.5mLDMF中，加入HATU 32mg，N，N-二异丙基乙胺51μL，室温下搅拌15min，加入3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基-1-(6-((4-(哌嗪-1-基)苯基)氨基)嘧啶-4-基)尿素30mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-4。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.58(s,1H),9.43(s,1H),8.37(s,1H),7.70(s,1H),7.47(t,J＝7.8Hz,1H),7.23(d,J＝8.5Hz,2H),7.06(d,J＝7.1Hz,1H),6.95(d,J＝8.4Hz,2H),6.86(d,J＝8.5Hz,1H),6.50(s,1H),6.21(t,J＝5.6Hz,1H),6.11(s,1H),4.90(dd,J＝11.9,5.4Hz,1H),3.90(s,6H),3.85–3.70(m,2H),3.63(t,J＝5.1Hz,2H),3.29(s,3H),3.29–3.08(m,6H),2.91–2.65(m,3H),2.37(t,J＝7.6Hz,2H),1.71–1.59(m,5H),1.45–1.33(m,6H).HRMS m/z:calcd for C45H50Cl2N10O8[M+H]+928.3,found 929.46。
实施例5：
制备:3-(2,6-二氯-3,5-二甲氧基苯基)-1-(6-((4-(4-(6-((2-(2,6-二氧代哌啶-3-基)-1,3)-二氧代异吲哚啉-4-基)氨基)己酰基)哌嗪-1-基)苯基)氨基)嘧啶-4-基)-1-甲基脲(ML-5)
制备方法：将6-((2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-4-基)氨基)己酸22mg加入1.5mLDMF中，加入HATU 32mg，N，N-二异丙基乙胺51μL，室温下搅拌15min，加入3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基-1-(6-((4-(哌嗪-1-基)苯基)氨基)嘧啶-4-基)尿素30mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-5。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.54(s,1H),9.22(s,1H),8.37(s,1H),7.68(s,1H),7.47(t,J＝7.8Hz,1H),7.24(d,J＝7.8Hz,2H),7.07(d,J＝7.1Hz,1H),6.96(d,J＝8.4Hz,2H),6.87(d,J＝8.5Hz,1H),6.50(s,1H),6.22(t,J＝5.6Hz,1H),6.11(s,1H),4.90(dd,J＝11.9,5.4Hz,1H),3.90(s,6H),3.83–3.76(m,2H),3.64(t,J＝5.1Hz,2H),3.32–3.23(m,5H),3.17(s,4H),2.91–2.65(m,4H),2.39(t,J＝7.4Hz,2H),1.71(h,J＝6.9Hz,4H),1.49(q,J＝8.2Hz,2H).HRMS m/z:calcd forC43H46Cl2N10O8[M+H]+900.3,found 901.33。
实施例6：
制备:2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)-N-(2-(2-(2,6-二氧哌啶-3-基)-1，3-二氧异吲哚啉-4-基)氨基)乙氧基)乙基)乙酰胺(ML-6)
制备方法：将2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酸酸30mg加入1.5mLDMF中，加入HATU 29mg，N，N-二异丙基乙胺45μL，室温下搅拌15min，加入4-((2-(2-氨基乙氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚-1,3-二酮18.3mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-6。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.59(s,1H),9.28(s,1H),8.36(s,1H),7.47(t,J＝7.8Hz,2H),7.31(s,1H),7.18(d,J＝8.4Hz,2H),7.08(d,J＝7.1Hz,1H),6.88(d,J＝8.4Hz,3H),6.51(s,1H),6.47(t,J＝5.6Hz,1H),6.09(s,1H),4.89(dd,J＝11.4,5.6Hz,1H),3.91(s,6H),3.71(t,J＝5.3Hz,2H),3.61(t,J＝5.1Hz,2H),3.57–3.50(m,2H),3.48–3.35(m,2H),3.29(s,3H),3.19(d,J＝15.9Hz,7H),2.98–2.58(m,7H).HRMS m/z:calcd for C43H47Cl2N11O9[M+H]+931.3,found 932.39。
实施例7：
制备:2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)-N-(2-(2-(2,6-二氧哌啶-3-基)-1，3-二氧异吲哚啉-4-基)氨基)乙氧基)乙氧基)乙基)乙酰胺(ML-7)
制备方法：将2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酸酸30mg加入1.5mLDMF中，加入HATU 29mg，N,N-二异丙基乙胺45μL，室温下搅拌15min，加入4-((2-(2-氨基乙氧基)乙氧基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮20.6mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-7。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),9.88(s,1H),8.36(s,1H),7.64(s,1H),7.46(dd,J＝14.7,7.0Hz,2H),7.19(d,J＝8.4Hz,2H),7.08(d,J＝7.1Hz,1H),6.91(d,J＝8.3Hz,2H),6.86(d,J＝8.5Hz,1H),6.51(s,1H),6.42(t,J＝5.6Hz,1H),6.10(s,1H),4.92(dd,1H),3.91(s,6H),3.81–3.63(m,6H),3.61(t,J＝5.1Hz,2H),3.51(q,J＝5.4Hz,2H),3.41(q,J＝5.7Hz,2H),3.29(s,3H),3.27–3.10(m,6H),2.93–2.58(m,8H).HRMS m/z:calcd for C45H51Cl2N11O10[M+H]+975.3,found976.32。
实施例8：
制备:2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)-N-(2-(2-(2-(2-((2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-4-基)氨基)乙氧基)乙氧基)乙氧基)乙基)乙酰胺(ML-8)
制备方法：将2-(4-(4-((6-(3-(2,6-二氯-3,5-二甲氧基苯基)-1-甲基脲基)嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酸酸30mg加入1.5mLDMF中，加入HATU 29mg，N,N-二异丙基乙胺45μL，室温下搅拌15min，加入4-((2-(2-(2-氨基乙氧基)乙氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮23mg，室温下搅拌30min。加入50mL水，并用二氯甲烷(20mL×3)萃取，合并有机相，饱和食盐水(50mL×3)洗涤有机相，无水硫酸钠干燥，真空浓缩有机相得到产物ML-8。
产物的核磁共振表征如下：1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),9.96(s,1H),8.37(d,J＝4.4Hz,1H),7.76–7.37(m,3H),7.21(d,J＝8.8Hz,2H),7.09(d,J＝7.1Hz,1H),6.94(d,J＝8.5Hz,2H),6.88(d,J＝8.6Hz,1H),6.52(s,1H),6.43(t,J＝5.4Hz,1H),6.10(s,1H),4.92(dd,J＝11.5,5.5Hz,1H),3.92(s,6H),3.74–3.53(m,13H),3.54–3.38(m,4H),3.36–3.11(m,10H),3.03–2.58(m,6H).HRMS m/z:calcd for C47H55Cl2N11O11[M+H]+1019.3,found 1020.31。
FGFR蛋白降解活性测试
将药物与FGFR高表达细胞KatoIII进行孵育6小时。随后用预冷的PBS洗涤2次，PMSF与PIPA裂解液以1:100的比例混合，冰上裂解细胞10min，4℃，12000r/min*20min离心，取上清，即细胞总蛋白，用BCA法定量检测蛋白量，用5微升蛋白上样缓冲液稀释蛋白后100℃变性5分钟。蛋白在SDS-PAGE电泳分离，转膜，封闭2小时，一抗4℃孵育过夜。TBST洗膜，二抗1:1000孵育2小时后显影，结果如图1所示。
图1为实施例1、4、6和7制得的化合物以及化合物BGJ398对FGFR的降解效果图，由图1可知，本发明实施例1、4、6和7制得的化合物ML-1、ML-4、ML-6、ML-7均具有较好的FGFR降解效果，而现有化合物BGJ398没有降解能力。
另外，实施例2-3、5、8制得的化合物对FGFR的降解效果与实施例1、4、6和7制得的化合物的效果相似。
以上所述的实施例对本发明的技术方案和有益效果进行了详细说明，应理解的是以上所述仅为本发明的具体实施例，并不用于限制本发明，凡在本发明的原则范围内所做的任何修改、补充和等同替换等，均应包含在本发明的保护范围之内。
Claims (7)
1.一种基于CRBN配体诱导FGFR降解的化合物，其特征在于，包括式(I)所示的化合物或其药学上可接受的盐：
其中，X为n为5、7或11；m为2或8；h为1或2。
2.一种药物组合物，其特征在于，包括如权利要求1所述的式(I)所示的化合物或其药学上可接受的盐；还包括药学上可接受的赋形剂。
3.一种药物组合物，其特征在于，包括如权利要求1所述的式(I)所示的化合物或其药学上可接受的盐，和不同的抗肿瘤药剂。
4.一种如权利要求1所述的化合物在或其药学上可接受的盐在制备预防和/或治疗癌症的药物中的应用。
5.根据权利要求4所述的应用，其特征在于，所述的癌症为多发性骨髓瘤、胃癌、肺癌、乳腺癌、食管癌、结肠癌、髓母细胞瘤、急性粒细胞白血病、慢性白血病、前列腺癌、肝细胞瘤、肾细胞瘤、宫颈癌、皮肤癌、卵巢癌、神经胶质瘤、甲状腺癌或胰腺癌。
6.一种如权利要求2或3所述的药物组合物在制备预防和/或治疗癌症的药物中的应用。
7.根据权利要求6所述的应用，其特征在于，所述的癌症为多发性骨髓瘤、胃癌、肺癌、乳腺癌、食管癌、结肠癌、髓母细胞瘤、急性粒细胞白血病、慢性白血病、前列腺癌、肝细胞瘤、肾细胞瘤、宫颈癌、皮肤癌、卵巢癌、神经胶质瘤、甲状腺癌或胰腺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210470131.0A CN114933589B (zh) | 2022-04-28 | 2022-04-28 | 基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210470131.0A CN114933589B (zh) | 2022-04-28 | 2022-04-28 | 基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114933589A CN114933589A (zh) | 2022-08-23 |
| CN114933589B true CN114933589B (zh) | 2024-03-26 |
Family
ID=82862752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210470131.0A Active CN114933589B (zh) | 2022-04-28 | 2022-04-28 | 基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114933589B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110305126A (zh) * | 2019-06-19 | 2019-10-08 | 浙江省医学科学院 | 一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用 |
| CN110372669A (zh) * | 2019-06-19 | 2019-10-25 | 浙江省医学科学院 | 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用 |
| CN110563703A (zh) * | 2019-09-18 | 2019-12-13 | 浙江省医学科学院 | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 |
| CN113747894A (zh) * | 2019-04-10 | 2021-12-03 | 丹娜-法伯癌症研究公司 | 成纤维细胞生长因子受体2(fgfr2)的降解剂 |
-
2022
- 2022-04-28 CN CN202210470131.0A patent/CN114933589B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113747894A (zh) * | 2019-04-10 | 2021-12-03 | 丹娜-法伯癌症研究公司 | 成纤维细胞生长因子受体2(fgfr2)的降解剂 |
| CN110305126A (zh) * | 2019-06-19 | 2019-10-08 | 浙江省医学科学院 | 一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用 |
| CN110372669A (zh) * | 2019-06-19 | 2019-10-25 | 浙江省医学科学院 | 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用 |
| CN110563703A (zh) * | 2019-09-18 | 2019-12-13 | 浙江省医学科学院 | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2;Du, Guangyan等;Angewandte Chemie, International Edition;第60卷(第29期);15905-15911 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114933589A (zh) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107709320B (zh) | 一种吡啶并氮杂环化合物及其制备方法和用途 | |
| JP2021522281A (ja) | がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤 | |
| WO2020259683A1 (zh) | 2，4-二取代嘧啶衍生物及其制备方法和用途 | |
| CN105164116A (zh) | 杂芳基取代的吲唑 | |
| WO2010003313A1 (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
| CN110563703B (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
| CN105452237A (zh) | 杂芳基取代的吡唑 | |
| WO2022156059A1 (zh) | Cdk6/dyrk2双靶点抑制剂及其制备方法和应用 | |
| CN107922348A (zh) | 双环杂环酰胺衍生物 | |
| CN107827875B (zh) | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 | |
| WO2022242321A1 (zh) | 一种PI3Kα选择性抑制剂及其制备方法和应用 | |
| WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
| CN104230952A (zh) | 含有嘧啶骨架的化合物及其制备方法和用途 | |
| CN101550136B (zh) | 双芳基脲类衍生物及其用于制备抗肿瘤药物的用途 | |
| CN104703599A (zh) | 作为蛋白激酶抑制剂的氨基异喹啉衍生物 | |
| CN105503863A (zh) | 新型抗肿瘤化合物 | |
| CN102108078A (zh) | 1,4-取代酞嗪类化合物及其制备方法和用途 | |
| CN114933589B (zh) | 基于crbn配体诱导fgfr降解的化合物及其制备方法和应用 | |
| CN115322158B (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
| CN111718325A (zh) | 一种2,4,5-取代嘧啶类化合物及其制备方法和应用 | |
| CN114940674B (zh) | 基于crbn配体诱导fgfr3-tacc3降解的化合物及其制备方法和应用 | |
| CN116120239A (zh) | 芳香六元环并咪唑类衍生物及其制备方法和应用 | |
| EP4324833A1 (en) | Alkynylphenylbenzamide compound and use thereof | |
| CN110229171A (zh) | 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用 | |
| CN102216280B (zh) | 双芳基脲类衍生物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |